



SINGAPORE O&G LTD.
(Company Registration No. 201100687M)

FOR IMMEDIATE RELEASE

SOG POSTED A DOUBLE-DIGIT INCREASE IN EARNINGS FOR 1H 2018

- **1H 2018 Group revenue increased by S\$2.6 million or 18.1% as compared to 1H 2017**
- **Excluding the one-off other income of S\$1.25 million and its related expenses, 1H 2018 Group net profit after tax increased by S\$1.2 million or 28.0% as compared to 1H 2017**
- **Declares an interim one-tier tax exempt dividend of 0.80 Singapore cents per share**

Singapore, 7 August 2018 – Singapore O&G Ltd. (“**SOG**”, the “**Company**” or collectively with its subsidiaries, the “**Group**”), a SGX Catalist listed company specialising in women’s and children’s health and wellness, announced today its unaudited financial results for the half year ended 30 June 2018 (“**1H 2018**”).

The Group’s revenue for 1H 2018 grew by S\$2.6 million or 18.1% as compared to the corresponding period ended 30 June 2017 (“**1H 2017**”). The increase is attributed to the increase of S\$1.4 million and S\$0.7 million revenue from our O&G and Cancer-related segment respectively, and the contribution of S\$0.5 million from our new Paediatrics segment.

Other income increased by S\$1.3 million or more than 100.0% from S\$90,000 for 1H 2017 to S\$1.4 million for 1H 2018. The increase is due largely to the receipt of the settlement sum of S\$1.25 million from the Company’s former Lead Independent Director, Mr. Christopher Chong Meng Tak (“**Mr. Chong**”), where the Company and Mr. Chong have, without any admission as to liability, agreed to a full and final settlement on the Company’s claim for S\$1.5 million from Mr. Chong for a transaction of the Company in which Mr. Chong was involved (the “**Dispute**”).

Consumables and medical supplies used increased by S\$0.4 million or 18.4% from S\$2.0 million for 1H 2017 to S\$2.4 million for 1H 2018. The increase parallels the increase in the Group’s revenue for the corresponding period.

Employee remuneration expense increased by S\$0.8 million or 14.7% from S\$5.6 million for 1H 2017 to S\$6.4 million for 1H 2018. The increase is due to an increase of S\$0.5 million accrual for 1H 2018 incentive bonus for a few specialist medical practitioners and S\$0.4 million from our new Paediatrics segment which started in July 2017; offset by the decrease of S\$0.1 million in accrual for 1H 2018 bonuses for Corporate Office.

Depreciation of plant and equipment increased by S\$40,000 or 16.5% from S\$240,000 for 1H 2017 to S\$280,000 for 1H 2018. The increase is attributed mainly to the depreciation charge arising from the two new laser machines acquired for our SOG Dermatology Clinic in June 2017 and August 2017, and renovation of Heng Clinic for Women and our Corporate Office at Mountbatten Square in May and July 2017 respectively.

Other operating expense increased by S\$0.3 million or 22.4% from S\$1.4 million for 1H 2017 to S\$1.7 million for 1H 2018. The increase is attributed mainly to a non-recurring professional and legal fees of S\$0.1 million incurred for the Dispute, and S\$0.2 million incurred by our new Paediatrics segment in 1H 2018.

Excluding the one-off other income arising from the Dispute and its related expenses, the Group's net profit after tax attributable to shareholders increased by S\$1.2 million or 28.0% from S\$4.1 million for 1H 2017 to S\$5.3 million for 1H 2018. Consequently, net profit margin increased by 2.4% from 29.1% for 1H 2017 to 31.5% for 1H 2018. Earnings per share increased by 0.24 Singapore cents or 27.6% from 0.87 Singapore cents for 1H 2017 to 1.11 Singapore cents for 1H 2018.

The Group maintained a strong financial position with a net asset value of S\$45.5 million as at 30 June 2018. This is an increase of S\$2.0 million or 4.6% as compared to S\$43.5 million as at 31 December 2017. Net asset value per share rose by 0.42 Singapore cents or 4.6% from 9.12 Singapore cents as at 31 December 2017 to 9.54 Singapore cents as at 30 June 2018.

The Board of Directors of SOG is pleased to declare an interim one-tier tax exempt dividend of 0.80 Singapore cents per share for FY 2018. The interim one-tier tax exempt dividend for FY 2017 was 0.61 Singapore cents per share.

Dr. Beh Suan Tiong, Executive Chairman of SOG said, "We are extremely delighted with the Group's performance, and with the double-digit growth in revenue and net profit after tax, for the first half of 2018. This is a remarkable team effort from our twelve specialist medical practitioners, clinical and management staff.

In celebrating this achievement, the Board of Directors is pleased to declare an interim one-tier tax exempt dividend of 0.80 Singapore cents per share for FY 2018 to thank all shareholders for your continued support and confidence in us!"

- END -

ABOUT SINGAPORE O&G LTD.

(“**SOG**” or collectively with its subsidiaries, the “**Group**”)

SOG is a leading group of specialist medical practitioners dedicated towards women’s and children’s health and wellness, with a long and established track record in the Obstetrics and Gynaecology (“**O&G**”) field in Singapore.

SOG is disciplined and focused in delivering a wide range of premier specialist services catering to the medical needs of women and children at affordable prices.

Currently, our spectrum of services include: pre-pregnancy counselling, delivery, pregnancy and post-delivery care, gynaecological and breast cancer, skin and aesthetic treatments, and paediatrics.

As at 30 June 2018, the Group has a total of twelve (12) specialist medical practitioners comprising:

- Six O&G Specialists;
- Three Cancer Specialists: One Gynae-Oncologist and two Breast and General Surgeons;
- Two Paediatricians; and
- One Dermatologist.

The Group is led by its Executive Chairman, Dr. Beh Suan Tiong and its Executive Directors, Dr. Lee Keen Whye and Dr. Heng Tung Lan. In particular, both Dr. Lee Keen Whye and Dr. Heng Tung Lan have more than 20 years’ experience in the O&G field.

For more information, please visit SOG’s website at www.sog.com.sg.

For media and analyst queries, please contact:

Investor Relations
Singapore O&G Ltd.
Tel: +65 6440 4123
Fax: +65 6440 8240
Email: ir@sog.com.sg

Alternatively, you may wish to contact Mr. Eric Choo, Chief Financial Officer, at:
Email: eric@sog.com.sg

*This press release has been prepared by the Company and its content have been reviewed by the Company’s Sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”), for compliance with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.*

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr. Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and Email: sponsorship@ppcf.com.sg).